Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Receivables: 2022-2025

Historic Receivables for InMed Pharmaceuticals (INM) over the last 4 years, with Jun 2025 value amounting to $465,104.

  • InMed Pharmaceuticals' Receivables rose 20.64% to $343,469 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 million, marking a year-over-year increase of 18.13%. This contributed to the annual value of $465,104 for FY2025, which is 31.82% up from last year.
  • Latest data reveals that InMed Pharmaceuticals reported Receivables of $465,104 as of FY2025, which was up 31.82% from $352,838 recorded in FY2024.
  • Over the past 5 years, InMed Pharmaceuticals' Receivables peaked at $465,104 during FY2025, and registered a low of $66,775 during FY2023.
  • Over the past 3 years, InMed Pharmaceuticals' median Receivables value was $352,838 (recorded in 2024), while the average stood at $294,906.
  • As far as peak fluctuations go, InMed Pharmaceuticals' Receivables fell by 24.14% in 2023, and later surged by 428.40% in 2024.
  • InMed Pharmaceuticals' Receivables (Yearly) stood at $88,027 in 2022, then dropped by 24.14% to $66,775 in 2023, then surged by 428.40% to $352,838 in 2024, then soared by 31.82% to $465,104 in 2025.